In people with type 2 diabetes and CKD, Ao-PWV did not change significantly from baseline after 24 weeks; final means were 9.65 m/s with lixisenatide and 9.96 m/s with placebo (p = 0.38).
In plain wordsIn people with diabetes and kidney disease, lixisenatide did not significantly change aortic stiffness compared with placebo.
- Peptide
- Lixisenatide
- Outcome
- No significant changeAortic pulse wave velocity
- Study
n = 90
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Vascular function · Cardiovascular
- Studied dose
- Dose not stated · 24 weeksAs given in this study (human).
Measurements
- Final mean Ao-PWV at 24 weeks
- 9.65 m/s
- lixisenatide (95% CI 9.17-10.13)
- Final mean Ao-PWV at 24 weeks
- 9.96 m/s
- placebo (95% CI 9.45-10.46)
- Between-group p value for Ao-PWV
- 0.38 p-value
- lixisenatide versus placebo
Source sentences
Ao-PWV did not change significantly from baseline after 24 weeks of treatment with final mean (95% confidence intervals) of 9.65 (9.17, 10.13) m/s with lixisenatide and 9.96 (9.45, 10.46) m/s with placebo, p = 0.38.
2 context sentences(design, population, supporting numbers)
We studied people with type 2 diabetes and CKD in a proof-of-concept single centre, randomised, double-blind parallel-group placebo-controlled study that evaluated 24 weeks' treatment with lixisenatide as compared to placebo on the primary endpoint of Ao-PWV.
In total, 101 participants (male 66%) were randomised of whom 90 were eligible for analyses (lixisenatide [n = 47] and placebo [n = 43]).